Stockscreener 앱 받기
65.00
1.05%
-0.69
시간 외 거래:
65.51
0.51
+0.78%
Arrowhead Pharmaceuticals Inc 주식(ARWR)의 최신 뉴스
Will Arrowhead Pharmaceuticals Inc. stock remain a Wall Street favoriteWeekly Earnings Recap & Weekly Market Pulse Updates - ulpravda.ru
How Arrowhead Pharmaceuticals Inc. (HDP1) stock moves in volatile trading sessions2025 Trading Volume Trends & Technical Pattern Based Signals - ulpravda.ru
Arrowhead Pharmaceuticals prices upsize convertible notes offering to $625M and stock offering at $64.50 - MSN
Will Arrowhead Pharmaceuticals Inc. (HDP1) stock hit Wall Street targets2025 Price Momentum & Weekly High Momentum Picks - ulpravda.ru
Portfolio Shifts: Can Arrowhead Pharmaceuticals Inc. stock surprise with earnings upsideShare Buyback & Risk Managed Investment Signals - ulpravda.ru
ARWR: Joint Management by Jefferies and JPMorgan in Recent Offering - GuruFocus
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants - BioSpace
Arrowhead Pharmaceuticals (ARWR) Unveils $625M Convertible Notes Offering - GuruFocus
Arrowhead Pharmaceuticals prices $625 million convertible notes offering - Investing.com
ARWR: Goldman Sachs Raises Arrowhead Pharma's Price Target to $8 - GuruFocus
Arrowhead Pharma (ARWR) Sees Target Price Boost by Morgan Stanley | ARWR Stock News - GuruFocus
Arrowhead Pharmaceuticals shares down 7.8% after co announces stock sale, convertible bond offering - MarketScreener
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China - BioSpace
Bernstein reiterates Market Perform rating on Arrowhead Pharma stock By Investing.com - Investing.com Canada
Arrowhead Pharmaceuticals (ARWR) Gains Approval in China for Red - GuruFocus
Arrowhead Pharma stock rating reiterated by Cantor Fitzgerald on obesity data - Investing.com Canada
Chardan Capital Raises Price Target for Arrowhead Pharma (ARWR) to $80.00 | ARWR Stock News - GuruFocus
Arrowhead (ARWR) Gains Approval in China for Redemplo - GuruFocus
Sanofi launches plozasiran in China following NMPA approval By Investing.com - Investing.com Australia
Sanofi launches plozasiran in China following NMPA approval - Investing.com
Arrowhead’s RNAi-based obesity drug combo shows benefit in Phase I/IIa trial - Clinical Trials Arena
Arrowhead Pharma stock holds steady as Goldman Sachs maintains Neutral rating - Investing.com Canada
Arrowhead Pharma stock price target raised to $84 from $81 at BofA - Investing.com UK
Arrowhead Pharmaceuticals plans to offer $700 million in securities By Investing.com - Investing.com Nigeria
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences - FinancialContent
Arrowhead Pharmaceuticals (ARWR) Surges on Promising Obesity The - GuruFocus
Arrowhead siRNA data in obesity mark POC for adipose delivery - BioCentury
Arrowhead (ARWR) Plans Convertible Notes and Stock Offerings - GuruFocus
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock - TradingView — Track All Markets
Arrowhead Pharmaceuticals Shares Surge on Health Canada Approval - StocksToTrade
Arrowhead Shoots For Obesity With RNAi, Shows Weight Loss Success - Citeline News & Insights
Arrowhead Pharmaceuticals Announces Interim Results from Obesity Treatment Trials - TradingView — Track All Markets
Arrowhead Pharmaceuticals: A Closer Look at the Recent Stock Activity - StocksToTrade
Arrowhead Pharmaceuticals: More Questions Than Answers After Obesity Data Update - Seeking Alpha
Arrowhead (ARWR) Stock Gains from Promising Drug Trial Results - GuruFocus
Arrowhead stock leaps after gene-silencing obesity drug doubles Lilly’s Zepbound weight loss - ts2.tech
Arrowhead Pharmaceuticals Gains as Health Canada Approves Redemplo - timothysykes.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Reaches New 52-Week HighTime to Buy? - MarketBeat
Arrowhead Enters Obesity Chat by Doubling Tirzepatide’s Weight Loss in Combo Study - BioSpace
Arrowhead Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:ARWR) - MarketBeat
Arrowhead Obesity Drugs Show Significant Fat Loss In Early Human Trials - Benzinga
Arrowhead Pharmaceuticals stock hits 52-week high at $72.95 By Investing.com - Investing.com Nigeria
Arrowhead’s RNAi trims fat in early PhI/IIa obesity data - The Pharma Letter
Arrowhead (ARWR) Reveals Promising Interim Results in Obesity Tr - GuruFocus
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition - BioSpace
Arrowhead gains as obesity therapy doubles weight loss with Lilly’s Zepbound (ARWR:NASDAQ) - Seeking Alpha
Arrowhead stock soars after obesity drug shows doubled weight loss By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals announces interim clinical data on RNAi-based obesity candidates - MarketScreener
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS - Yahoo Finance
Arrowhead Pharma Shares in Focus After $2.5M Insider Sale - Eudaimonia and Co
Arrowhead Pharmaceuticals (ARWR) Is Down 5.0% After First-in-Class FCS siRNA Approval in Canada - Yahoo Finance
Arrowhead Pharmaceuticals (NASDAQ:ARWR) COO Sells $3,123,503.23 in Stock - MarketBeat
Insider Selling: Arrowhead Pharmaceuticals (NASDAQ:ARWR) CEO Sells 13,187 Shares of Stock - MarketBeat
0.80%
4.56%
자본화:
|
볼륨(24시간):